The Genetics of Vitiligo

Journal of Investigative Dermatology

Volumn 131, Issue , 2011, Pages E18-E20

  Spritz, Richard A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANIN;

AUTOIMMUNITY; CELL PROLIFERATION; EPIDERMIS; GENETICS; HUMAN; IMMUNOLOGY; MELANOCYTE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SKIN PIGMENTATION; VITILIGO;

AUTOIMMUNITY; CELL PROLIFERATION; EPIDERMIS; HUMANS; MELANINS; MELANOCYTES; SKIN PIGMENTATION; VITILIGO;

EID: 84856167992     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/skinbio.2011.7     Document Type: Article

References (22)

1. Addison, T., On the constitutional and local effects of disease of the suprarenal capsules. Addison, Thomas M.D, (eds.) Physician to Guy's Hospital, New Sydenham Society, 1937, Reprinted in Med Classics, London, 244–293.
2. Brito P.S., On leucoderm, vitiligo, ven kuttam (Tamil) or cabbare (Singhalese), and several new methods of treatment. Br Med J, 1, 1885, 834–835.
3. Burdick K.H., Hawk W.A., Vitiligo in a case of vaccinia virus-treated melanoma. Cancer 17 (1964), 7208–7212.
4. Das S.K., Majumder P.P., Majumdar T.K., et al. Studies on vitiligo. II. Familial aggregation and genetics. Genet Epidemiol, 2, 1985, 255–262.
5. El Mofty A.M., A preliminary clinical report on the treatment of leukoderma with Ammi majus Linn. J Roy Egyptian MA, 31, 1948, 651–655.
6. Gross A., Tapia F.J., Mosca W., Mononuclear cell subpopulations and infiltrating lymphocytes in erythema dyschromicum perstans and vitiligo. Histol Histopathol, 2, 1987, 277–283.
7. Hebra F., Kaposi M., On Diseases of the Skin, Including the Exanthemata. trans, Tay W., (eds.) vol. III., 1874, New Sydenham Society, London.
8. Hu F., Fosnaugh R.P., Lesney P.F., In vitro studies on vitiligo. J Invest Dermatol, 33, 1959, 267–280.
9. Jin Y., Birlea S.A., Fain P.R., et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. New Engl J Med, 362, 2010, 1686–1697.
10. Jin Y., Mailloux C.M., Gowan K., et al. NALP1in vitiligo-associated multiple autoimmune disease. New Engl J Med, 356, 2007, 1216–1225.
11. Köbner H., Zur aetiologie der psoriasis. Vjschr Dermatol, 8, 1876, 559–561.
12. Langhof H., Feuerstein M., Schabinski G., Melaninantikorperbildung bei vitiligo. Hautarzt, 16, 1965, 209–221.
13. Lerner A.B., Vitiligo. J Invest Dermatol, 32, 1959, 285–310.
14. Lindsay H.C.L., Leukoderma-its treatment. Cal West Med, 37, 1932, 36–41.
15. Menon A.N., Ultra-violet therapy in cases of leukoderma. Ind Med Gaz, 80, 1945, 612–614.
16. Nath S.K., Kelly J.A., Namjou B., et al. Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet, 69, 2001, 1401–1406.
17. Neufeld M., Blizzard R.M., Polyglandular autoimmune diseases. Pinchera, A., Doniach, D., Fenzi, G.F., (eds.) In Symposium on Autoimmune Aspects of Endocrine Disorders., 1980, Academic Press, New York, 357–365.
18. Quan C., Ren Y.Q., Xiang L.H., et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet, 42, 2010, 614–618.
19. Schmidt M., Eine biglanduiare Erkrankung (Nebennieren und Schilddruse) bei Morbus Addisonii. Verh Dtsch Ges Pathol, 21, 1926, 212–221.
20. Stuttgen G., Die Vitiligo in erbbiologischer Betrachtung. Z Haut Geschlechtskr, 9, 1950, 451–457.
21. Teindel H., Familiäre Vitiligo. Z Haut Geschlechtskr, 9, 1950, 457–462.
22. van Geel N.A., Mollet I.G., De Schepper S., et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res, 23, 2010, 375–384.